ESMO 2025 | Assessing the real-world side effects of T-DXd in HER2+ breast cancer
Jean-Yves Pierga, MD, Institut Curie, Paris, France, comments the utility of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive breast cancer, regardless of patient performance status or age, including those over 70 years old. The real-world side effects of T-DXd, primarily hematological, were manageable, and the incidence of pneumonitis, a lung toxicity, was consistent with other clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The main result was the fact that it was usable in routine practice without selecting the patient based on the performance status or age, because we have patients who are aged more than 70 years. And for example, for side effects, we have mainly hematological side effects, which was already known and quite manageable. And for example, for this specific side effect, which was pneumonitis, so for this lung toxicity, we had exactly the same rates in other clinical trials, about 40% in all grades and 1% of grade 5 in this cohort of patients...
The main result was the fact that it was usable in routine practice without selecting the patient based on the performance status or age, because we have patients who are aged more than 70 years. And for example, for side effects, we have mainly hematological side effects, which was already known and quite manageable. And for example, for this specific side effect, which was pneumonitis, so for this lung toxicity, we had exactly the same rates in other clinical trials, about 40% in all grades and 1% of grade 5 in this cohort of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
